<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598789</url>
  </required_header>
  <id_info>
    <org_study_id>Allo MM HSCT</org_study_id>
    <nct_id>NCT04598789</nct_id>
  </id_info>
  <brief_title>A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors</brief_title>
  <official_title>Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were&#xD;
      chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence,&#xD;
      relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with&#xD;
      ATG-CSA-MTX or PTCy-MMF-FK506&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>acute GvHD incidence</measure>
    <time_frame>2012-2017</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention, observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients (children and adults) having HSCT from a one-antigen mismatch unrelated donors and&#xD;
        treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children and adults)&#xD;
&#xD;
          -  HSCT from a one-antigen mismatch unrelated donors&#xD;
&#xD;
          -  Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017&#xD;
&#xD;
        Exclusion Criteria: none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celeste Cagnazzo, PhD</last_name>
    <phone>00390113135171</phone>
    <email>celeste.cagnazzo@unito.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Citt√† della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Cagnazzo, PhD</last_name>
      <phone>00390113135171</phone>
      <email>celeste.cagnazzo@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</investigator_affiliation>
    <investigator_full_name>Prof. Franca Fagioli</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

